PPT-Disparities in Prostate Cancer Outcomes: Race, Access, and Ancestry

Andrew J Armstrong MD ScM FACP National Alliance of State Prostate Cancer Coalitions Webinar Series November 2020 Professor of Medicine and Surgery Pharmacology and Cancer Biology Director of Research Duke Cancer Institute . Norm D. Smith, M.D.. Associate Professor. Co-Director. Urologic Oncology. University of Chicago. United States Preventive Services Task Force (USPSTF). USPSTF Warns Against Blood Test For Prostate Cancer. . Julian Mander . RPH Urology. Social Conditions and Racial and Ethnic Patterns of Cognitive Aging. Jennifer Manly. APHA Oct . 2016. . Presenter Disclosures. (1) The following personal financial relationships with commercial interests relevant to this presentation existed during the past 12 months:. This program will include a discussion of investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a . Ruth Etzioni. Roman Gulati . Lurdes . inouE. Dhamanpreet. Kaur. Fred Hutchinson cancer research center. TODAY’S PRESENTATION. Trends in prostate cancer incidence and mortality. What are the trends really telling us? A mathematical model. The second most common cancer diagnosed in men. The incidence increase with age very rare before age of 40, more in western countries particularly Scandinavian countries (low light exposure), and black men are at greatest risk. The prostate is a gland the size of a walnut it sits at the neck of the bladder. Only men have a prostate gland!. Prostate cancer is the commonest type of male cancer . By far the biggest risk factor is age . If you decide not to get screened, you can always change your mind later. If you decide to get screened, it does not mean you have to go to the next step. You should discuss each step with your docto Thomas M. Schroeder, MD November 14. th. , 2020. Outline. Overview of All Localized Treatments for Prostate Cancer. Interesting Important Recent Developments. Active Surveillance, Radiation, or Surgery. Latest developments. . Prof.. . Neeraj Agarwal, MD. Director, Genitourinary Oncology Program, . Huntsman Cancer Institute, University of Utah, USA. MARCH 2022. PARPi. , poly-ADP ribose polymerase inhibitors. Victoria . Sinibaldi. , RN, MS, CS, CANP, BC. Daniel P . Petrylak. , MD. . Disclosures for . Ms. . Sinibaldi. No financial interests or affiliations to disclose. Disclosures for Dr . Petrylak. Consulting Agreements. Rishindra M. Reddy, MD, MBA, FACS. Professor, University of Michigan, . Section of Thoracic Surgery. Jose Jose Alvarez Professor of Thoracic Oncology Research. THORACIC SURGERY. Disclosures. Intuitive Surgical. Dr Marie-Pier St-Laurent, MD, FRCSC. Urologic-Oncology fellow, UBC. Research scientist, Vancouver Prostate Centre. Honorarium: Bayer, PCSC. As a urologist, I am biased towards prostate cancer screening.. for Spinal Cord Injury. Larissa Myaskovsky, PhD. Associate Professor of Medicine, Psychiatry and Clinical and Translational Science. University of Pittsburgh School of Medicine. and. VA Pittsburgh Healthcare System.